JUBLPHARMA Stock Overview
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Jubilant Pharmova Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹677.80 |
| 52 Week High | ₹724.40 |
| 52 Week Low | ₹300.60 |
| Beta | 1.58 |
| 1 Month Change | 19.54% |
| 3 Month Change | 19.17% |
| 1 Year Change | 125.11% |
| 3 Year Change | -13.31% |
| 5 Year Change | 3.62% |
| Change since IPO | 702.42% |
Recent News & Updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?
Sep 20Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Sep 08Should You Take Comfort From Insider Transactions At Jubilant Life Sciences Limited (NSE:JUBILANT)?
Sep 03Jubilant Life Sciences Limited's (NSE:JUBILANT) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Aug 24Shareholder Returns
| JUBLPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.3% | -0.1% | 1.8% |
| 1Y | 125.1% | 55.9% | 46.4% |
Price Volatility
| JUBLPHARMA volatility | |
|---|---|
| JUBLPHARMA Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 5,778 | Priyavrat Bhartia | www.jubilantpharmova.com |
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.
Jubilant Pharmova Limited Fundamentals Summary
| JUBLPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹107.64b |
| Earnings (TTM) | ₹378.20m |
| Revenue (TTM) | ₹66.22b |
284.6x
P/E Ratio1.6x
P/S RatioIs JUBLPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JUBLPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹66.22b |
| Cost of Revenue | ₹21.43b |
| Gross Profit | ₹44.79b |
| Other Expenses | ₹44.41b |
| Earnings | ₹378.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 67.64% |
| Net Profit Margin | 0.57% |
| Debt/Equity Ratio | 67.9% |
How did JUBLPHARMA perform over the long term?
See historical performance and comparison